vs

Side-by-side financial comparison of Cambium Networks Corp (CMBM) and Connect Biopharma Holdings Ltd (CNTB). Click either name above to swap in a different company.

Cambium Networks Corp is the larger business by last-quarter revenue ($40.3M vs $24.1M, roughly 1.7× Connect Biopharma Holdings Ltd). Connect Biopharma Holdings Ltd runs the higher net margin — 61.6% vs -17.9%, a 79.5% gap on every dollar of revenue.

Cambium Networks Corporation is an American manufacturer of wireless telecommunications equipment, including Enterprise WiFi, Network switch, Internet of Things, and fixed wireless broadband and Wi-Fi for enterprises products for Internet access. Publicly traded on the NASDAQ stock exchange, it spun out of Motorola in October 2011.

Connect Biopharma Holdings Ltd is a clinical-stage global biopharmaceutical company dedicated to developing innovative targeted therapies for inflammatory, immunological and autoimmune diseases. Its core pipeline includes candidate treatments for asthma, atopic dermatitis and other conditions with high unmet medical needs, with main operations across the U.S., China and key global markets to deliver effective therapeutic solutions to patients.

CMBM vs CNTB — Head-to-Head

Bigger by revenue
CMBM
CMBM
1.7× larger
CMBM
$40.3M
$24.1M
CNTB
Higher net margin
CNTB
CNTB
79.5% more per $
CNTB
61.6%
-17.9%
CMBM

Income Statement — Q4 FY2024 vs Q2 FY2024

Metric
CMBM
CMBM
CNTB
CNTB
Revenue
$40.3M
$24.1M
Net Profit
$-7.2M
$14.8M
Gross Margin
36.6%
Operating Margin
-28.4%
56.6%
Net Margin
-17.9%
61.6%
Revenue YoY
-23.2%
Net Profit YoY
71.0%
148.7%
EPS (diluted)
$-0.26
$0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CMBM
CMBM
CNTB
CNTB
Q4 24
$40.3M
Q3 24
$44.7M
Q2 24
$45.2M
$24.1M
Q1 24
$47.1M
Q4 23
$52.5M
Q3 23
$44.6M
Q2 23
$53.7M
$0
Q1 23
$76.0M
Net Profit
CMBM
CMBM
CNTB
CNTB
Q4 24
$-7.2M
Q3 24
$-34.5M
Q2 24
$-14.2M
$14.8M
Q1 24
$-18.4M
Q4 23
$-24.9M
Q3 23
$-36.4M
Q2 23
$-13.4M
$-30.5M
Q1 23
$671.0K
Gross Margin
CMBM
CMBM
CNTB
CNTB
Q4 24
36.6%
Q3 24
43.6%
Q2 24
32.5%
Q1 24
29.8%
Q4 23
15.2%
Q3 23
26.7%
Q2 23
39.0%
Q1 23
47.4%
Operating Margin
CMBM
CMBM
CNTB
CNTB
Q4 24
-28.4%
Q3 24
-69.6%
Q2 24
-27.2%
56.6%
Q1 24
-33.1%
Q4 23
-44.5%
Q3 23
-46.2%
Q2 23
-20.9%
Q1 23
1.9%
Net Margin
CMBM
CMBM
CNTB
CNTB
Q4 24
-17.9%
Q3 24
-77.3%
Q2 24
-31.5%
61.6%
Q1 24
-39.2%
Q4 23
-47.5%
Q3 23
-81.5%
Q2 23
-25.0%
Q1 23
0.9%
EPS (diluted)
CMBM
CMBM
CNTB
CNTB
Q4 24
$-0.26
Q3 24
$-1.22
Q2 24
$-0.51
$0.27
Q1 24
$-0.66
Q4 23
$-0.90
Q3 23
$-1.32
Q2 23
$-0.49
$-0.55
Q1 23
$0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CMBM
CMBM
CNTB
CNTB
Cash + ST InvestmentsLiquidity on hand
$110.2M
Total DebtLower is stronger
$67.6M
Stockholders' EquityBook value
$-3.2M
$110.9M
Total Assets
$173.7M
$120.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CMBM
CMBM
CNTB
CNTB
Q4 24
Q3 24
Q2 24
$110.2M
Q1 24
Q4 23
Q3 23
Q2 23
$81.6M
Q1 23
Total Debt
CMBM
CMBM
CNTB
CNTB
Q4 24
$67.6M
Q3 24
$67.6M
Q2 24
$68.9M
Q1 24
$63.8M
Q4 23
$25.1M
Q3 23
$25.8M
Q2 23
$26.4M
Q1 23
$27.0M
Stockholders' Equity
CMBM
CMBM
CNTB
CNTB
Q4 24
$-3.2M
Q3 24
$1.9M
Q2 24
$34.1M
$110.9M
Q1 24
$45.0M
Q4 23
$61.1M
Q3 23
$82.5M
Q2 23
$116.5M
$128.7M
Q1 23
$125.8M
Total Assets
CMBM
CMBM
CNTB
CNTB
Q4 24
$173.7M
Q3 24
$194.3M
Q2 24
$221.1M
$120.6M
Q1 24
$219.8M
Q4 23
$209.1M
Q3 23
$222.4M
Q2 23
$275.7M
$144.1M
Q1 23
$280.4M
Debt / Equity
CMBM
CMBM
CNTB
CNTB
Q4 24
Q3 24
36.12×
Q2 24
2.02×
Q1 24
1.42×
Q4 23
0.41×
Q3 23
0.31×
Q2 23
0.23×
Q1 23
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CMBM
CMBM
CNTB
CNTB
Operating Cash FlowLast quarter
$-10.4M
$-8.0M
Free Cash FlowOCF − Capex
$-10.8M
FCF MarginFCF / Revenue
-26.8%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
-0.54×
TTM Free Cash FlowTrailing 4 quarters
$-21.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CMBM
CMBM
CNTB
CNTB
Q4 24
$-10.4M
Q3 24
$8.9M
Q2 24
$2.4M
$-8.0M
Q1 24
$-15.9M
Q4 23
$-5.8M
Q3 23
$-345.0K
Q2 23
$-4.5M
$-31.2M
Q1 23
$-6.1M
Free Cash Flow
CMBM
CMBM
CNTB
CNTB
Q4 24
$-10.8M
Q3 24
$6.8M
Q2 24
$87.0K
Q1 24
$-17.4M
Q4 23
$-7.4M
Q3 23
$-1.5M
Q2 23
$-5.2M
Q1 23
$-7.5M
FCF Margin
CMBM
CMBM
CNTB
CNTB
Q4 24
-26.8%
Q3 24
15.2%
Q2 24
0.2%
Q1 24
-37.0%
Q4 23
-14.0%
Q3 23
-3.3%
Q2 23
-9.7%
Q1 23
-9.9%
Capex Intensity
CMBM
CMBM
CNTB
CNTB
Q4 24
1.1%
Q3 24
4.8%
Q2 24
5.1%
Q1 24
3.3%
Q4 23
3.1%
Q3 23
2.5%
Q2 23
1.2%
Q1 23
1.9%
Cash Conversion
CMBM
CMBM
CNTB
CNTB
Q4 24
Q3 24
Q2 24
-0.54×
Q1 24
Q4 23
Q3 23
Q2 23
Q1 23
-9.06×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CMBM
CMBM

Enterprise$16.6M41%
Point To Multi Point$16.4M41%
Other$5.8M14%

CNTB
CNTB

Segment breakdown not available.

Related Comparisons